Device Trial Radar · NCT05932615
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
1,500
Planned (sponsor's estimate)
Start
Mar 15, 2024
Primary completion
Apr 2027
Study completion Apr 2036
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- First posted
- Jul 6, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of ENVISION is to evaluate the safety and effectiveness of the Navitor Transcatheter Aortic Valve Implantation (TAVI) System for treating patients with symptomatic, severe native aortic stenosis who are considered intermediate or low risk for surgical mortality. The trial will also evaluate the safety and effectiveness of the Navitor TAVI System in a valve-in-valve (ViV) application in patients with symptomatic heart disease due to failure of a surgical or transcatheter bioprosthetic aortic valve who are at high or greater surgical risk. In addition, the trial will assess the safety of the Navitor TAVI System for the treatment of symptomatic, severe native aortic stenosis in patients with bicuspid aortic valve anatomy, irrespective of surgical risk classification.
Conditions
- Aortic Valve Stenosis
- Heart Valve Diseases
- Aortic Valve Disease
- Heart Disease Structural Disorder
Interventions
Navitor Transcatheter Aortic Valve Implantation (TAVI) SystemDevice
TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
Any Commercially Available Transcatheter Aortic Valve (CAV) SystemDevice
TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of all-cause mortality or all strokeTime frame: At 12 months post-procedure
Locations
107 sites in 13 countries. Site status is shown where the registry gives one.
University Hospital - Univ. of Alabama at Birmingham (UAB)
Birmingham, Alabama
St. Joseph's Hospital & Medical Center
Phoenix, Arizona
Tucson Medical Center
Tucson, Arizona
104 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.